GlassScriptPhysician profile
Leonard Michael Dileo
NPI 1831161710
$3,476.63
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,725 · 2020: $582 · 2021: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $683.73 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $576.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $524.32 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $308.32 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $305.64 | 2019 | |
| Neurocrine Biosciences, INC. | $290.69 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $134.13 | 2019 | |
| Lundbeck LLC | $123.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $103.52 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $94.02 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $89.06 | 2019-2021 | |
| Abbvie INC. | $75.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.42 | 2021 | |
| Shire North American Group INC | $31.78 | 2019 | |
| Acadia Pharmaceuticals INC | $18.68 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.15 | 2019 | |
| Supernus Pharmaceuticals, INC. | $17.73 | 2021 | |
| Almatica Pharma LLC | $17.33 | 2021 | |
| Livanova USA, INC. | $12.45 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.15 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Dileo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.